t
| Date | 31 Jan 2022 |
| Time | 07:00:07 |
| Category | Miscellaneous |
| ID | 0490A |
31 January 2022
N4 Pharma Plc
("N4 Pharma" or the "Company")
Granting of Patents
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that the University of Queensland has informed the Company that it has been notified by the US patent attorney of the granting of its patent application in relation to Nuvec® in the United States and by the Chinese authorities of the granting of a patent in China. N4 Pharma has the exclusive worldwide rights to Nuvec® for therapeutic uses in humans and animals.
The granted patent in the USA will specifically cover the matter of composition of the nanoparticle made using a broad description of the manufacturing process used by the Company. The University of Queensland has also informed the Company it will file a continuation patent application in the USA for a matter of composition patent independent of the manufacturing process to match the patents granted in Europe, Japan, Australia and China.
Nigel Theobald, Chief Executive Officer of the Company, commented: "We are delighted to receive notification of this allowance to grant our licensed patent in these critical and influential markets.
"The granting of this USA nanoparticle patent using a broad description of the manufacturing process adds to the other granted patents giving us strong intellectual property protection in the key territories across the world which is a vital component for potential licensing deals"
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which has been incorporated into UK law by the European Union (Withdrawal) Act 2018.
Enquiries:
|
N4 Pharma Plc Nigel Theobald, CEO Luke Cairns, Executive Director |
Via IFC Advisory |
|
|
|
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking) |
Tel: +44 (0)20 3470 0470 |
|
|
|
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker |
Tel: +44 (0)20 3657 0050
|
|
IFC Advisory Limited Financial PR Graham Herring Zach Cohen |
Tel: +44 (0)20 3934 6630 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.